Scholarlink

<p>Aminopyridines (APs) enhance Purkinje cell excitability and are effective for several cerebellar and ocular motor syndromes, including downbeat nystagmus. Their use in anti–glutamic acid decarboxylase (GAD) cerebellar ataxia has not previously been described. A 69-year-old woman with confirmed anti-GAD cerebellar ataxia underwent clinical and videonystagmography (VNG) assessments at baseline, Day 7, and Day 30 after start of fampridine 20&#xa0;mg/day. Baseline VNG showed pronounced downbeat nystagmus and frequent square-wave jerks. By Day 7, downbeat nystagmus had fully resolved with a marked reduction in square-wave jerks, accompanied by improvement in oscillopsia and diplopia. Findings remained stable at Day 30. SARA scores remained unchanged, with persistent gait, stance, and other cerebellar motor deficits. Fampridine was associated with rapid and sustained improvement in oculomotor dysfunction in this patient with anti-GAD cerebellar ataxia. APs may offer adjunctive symptomatic benefit in selected individuals with visually disabling downbeat nystagmus. Controlled studies are needed to confirm these observations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Aminopyridines on Oculomotor Dysfunction in Anti-GAD Ataxia: A Brief Report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Pavol Skacik,
  • Milan Grofik,
  • Egon Kurca,
  • Stefan Sivak

摘要

Aminopyridines (APs) enhance Purkinje cell excitability and are effective for several cerebellar and ocular motor syndromes, including downbeat nystagmus. Their use in anti–glutamic acid decarboxylase (GAD) cerebellar ataxia has not previously been described. A 69-year-old woman with confirmed anti-GAD cerebellar ataxia underwent clinical and videonystagmography (VNG) assessments at baseline, Day 7, and Day 30 after start of fampridine 20 mg/day. Baseline VNG showed pronounced downbeat nystagmus and frequent square-wave jerks. By Day 7, downbeat nystagmus had fully resolved with a marked reduction in square-wave jerks, accompanied by improvement in oscillopsia and diplopia. Findings remained stable at Day 30. SARA scores remained unchanged, with persistent gait, stance, and other cerebellar motor deficits. Fampridine was associated with rapid and sustained improvement in oculomotor dysfunction in this patient with anti-GAD cerebellar ataxia. APs may offer adjunctive symptomatic benefit in selected individuals with visually disabling downbeat nystagmus. Controlled studies are needed to confirm these observations.